# US 10,864,224 B2 · Synthetic composition for treating antibiotic associated complications

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,864,224 B2
- Document ID: US10864224B2
- Status: Granted
- Kind: B2
- Application number: 15/776,654
- Filed: 2016-11-17
- Published: 2018-11-15
- Granted: 2020-12-15
- Earliest claimed: 2015-11-17
- Assignees: Glycom A/S
- Applicants: Glycom A/S
- Inventors: Bruce McConnell; Louise Kristine Vigsnæs; David Paul Kronlage
- Web page: https://patentgrep.com/patent/US10864224B2

## CPC

- A61K 31/702: Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
- A23L 33/125: containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates (indigestible substances A23L33/21)
- A61P 31/04: Antibacterial agents
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The invention relates to a synthetic composition comprising human milk oligosaccharides for use in at least partially restoring the commensal gastrointestinal microbiota and preventing or mitigating antibiotic associated diarrhoea.

## Claims

### Claim 1

A method for treating or reducing risk of a disorder associated with antibiotic therapy comprising
administering daily to a human in need thereof at least 2 g of a mixture consisting of 2′-FL and LNnT, wherein the ratio of 2′-FL and LNnT is from about 1.5:1 to about 5:1 by weight
wherein the disorder associated with antibiotic therapy is selected from the group consisting of diarrhoea, dysbiosis of the lower gastro-intestinal tract, and primary or recurrent Clostridium difficile infection, and wherein the human is undergoing or had previously undergone antibiotic therapy.

### Claim 2 (depends on 1)

The method according to claim 1, in which the mixture is administered neat, as diluted with water or in the form of a synthetic composition in one or more unit dosage forms.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the amount of the mixture is from about 2 g to about 10 g.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the mixture is administered daily during the treatment period and for at least 14 days after termination of antibiotic therapy, or at least 14 days after termination of antibiotic therapy.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the human is a child of 3 years of age or older or an elderly person of 60 years of age or older.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the antibiotic therapy comprises a broad spectrum antibiotic.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the reducing risk of a disorder includes reducing the long-term health risks associated with antibiotic treatment.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the long-term health risk is a disease or condition selected from the group consisting of autoimmune or metabolic diseases, diarrhoea, ulcerative colitis, impaired immune function, obesity, food absorption, depression, sepsis, asthma and allergies.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the mixture is effective to increase the abundance of Bifidobacterium of the B. adolescentis phylogenetic group in the human.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the disorder is diarrhoea.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the disorder is dysbiosis of the lower gastro-intestinal tract.

### Claim 12 (depends on 1)

The method according to claim 1, wherein the disorder is primary or recurrent Clostridium difficile infection.